Skip to main content

Advertisement

SpringerLink
Log in

Multi-Modality Therapy for Cancer of the Esophagus and GE Junction

  • Gastrointestinal Cancers (AB Benson, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Cancers of the esophagus and gastroesophageal junction (GEJ) are associated with a high mortality rate. In the United States, the incidence of adenocarcinoma of the distal esophagus and GEJ is rising at an alarming rate. Decades of investigation have established the impact on survival of neoadjuvant platinum-based chemotherapy as well as chemoradiation for locally advanced tumors. Distant recurrence remains the most common pattern of failure and efforts to improve therapeutic outcome should focus on optimizing systemic therapy. Induction chemotherapy before preoperative chemoradiation and postoperative adjuvant chemotherapy are approaches to intensify systemic therapy delivery and deserve further investigation. The integration of targeted therapies and development of predictive biomarkers to identify subgroups of patients who are likely to benefit will mark the future of neoadjuvant treatment in this disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of Importance

  1. Kamanagar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.

    Article  Google Scholar 

  2. Eslick GD. Epidemiology of esophageal cancer. Gastroenterol Clin North Am. 2009;38:17–25.

    Article  PubMed  Google Scholar 

  3. Siewert JR, Stein HJ, Feith M, et al. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at single center in the Western world. Ann Surg. 2001;234:360–7.

    Article  PubMed  CAS  Google Scholar 

  4. Mariette C, Finzi L, Piessen G, et al. Esophageal carcinoma: prognostic differences between squamous cell carcinoma and adenocarcinoma. World J Surg. 2005;29:39–45.

    Article  PubMed  Google Scholar 

  5. Lagergen J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825–31.

    Article  Google Scholar 

  6. Freedman ND, Abnet CC, Leitzmann MF, et al. A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol. 2007;165:1424–33.

    Article  PubMed  Google Scholar 

  7. Zhang HL, Chen LQ, Liu RL, et al. The number of lymph node metastases influences survival and IUC TNM classification for esophageal squamous cell carcinoma. Dis Esophagus. 2010;23:53.

    Article  PubMed  CAS  Google Scholar 

  8. Peyre CG, Hagen JA, DeMeester SR, et al. Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann Surg. 2008;248:979.

    Article  PubMed  Google Scholar 

  9. Choi J, Kim SG, Kim JS, et al. Comparison of endoscopic ultrasound, positron emission tomography and computed tomography in the preoperative locoregional staging of resectable esophageal cancer. Surg Endosc. 2010;24:1380–6.

    Article  PubMed  Google Scholar 

  10. Fisher JM, Pohl H, Gordon SR, et al. The impact of time elapsed between endoscopic ultrasound and esophagectomy on concordance of ultrasonographic and pathologic staging of esophageal malignancy. Dig Dis Sci. 2011;56:2987–91.

    Article  PubMed  Google Scholar 

  11. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19:3058–65.

    PubMed  CAS  Google Scholar 

  12. Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2006;24:4692–8.

    Article  PubMed  Google Scholar 

  13. Wong R, Walker-Dilks C, Raifu A. Evidence-based guideline recommendations on the use of PET imaging in esophageal cancer. Clin Oncol. 2012;24:86–104.

    Article  CAS  Google Scholar 

  14. Schreurs LM, Busz DM, Paardekooper GM, et al. Impact of 18-FDG PET on CT defined target volumes in radiation treatment planning of esophageal cancer: reduction in geographic misses with equal inter-observer variability: PET/CT improves esopghageal target definition. Dis Esophagus 2010;23:493–501.

    Article  PubMed  CAS  Google Scholar 

  15. Kelsen DP, Winter KA, Gunderson LL, et al. Long-term results of RTOG trial 8911 (USA Intergroup 113): A random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007;25:3719–25.

    Article  PubMed  Google Scholar 

  16. Meguid RA, Hooker CM, Taylor JT, et al. Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: does the pattern of recurrence differ for patients with complete response and those with partial or no response? J Thorac Cardiovasc Surg. 2009;138:1309–17.

    Article  PubMed  Google Scholar 

  17. Berger AG, Farma J, Scott WJ, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal cancer is associated with significantly improved survival. J Clin Oncol. 2005;23:4330–7.

    Article  PubMed  Google Scholar 

  18. Medical Research Council Esophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in esophageal cancer: a randomized controlled trial. Lancet. 2002;359:1727–33.

    Article  Google Scholar 

  19. Allum WH, Stenning SP, Bancewicz J, et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27:5062–7.

    Article  PubMed  Google Scholar 

  20. Boige V, Pignon J, Saint-Aubert B, et al. Final results of a randomized trial comparing preoperative 5-fluorouracil/cisplatin to surgery alone in adenocarcinoma of stomach and lower esophagus: FNLCC ACCORD07-FFCD 9703 trial. JCO. 2007;25(18S):4510.

    Google Scholar 

  21. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.

    Article  PubMed  CAS  Google Scholar 

  22. Thirion PG, Michiels S, Le Maltre A, et al. Individual patient data-based meta-analysis assessing pre-operative chemotherapy in resectable esophageal cancer. J Clin Oncol 2007;25S:Abstract 4512.

  23. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable esophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011;12:681–692.

    Article  PubMed  Google Scholar 

  24. Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335:462–7.

    Article  PubMed  CAS  Google Scholar 

  25. Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19:305–13.

    PubMed  CAS  Google Scholar 

  26. Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the esophagus: a randomized controlled phase III trial. Lancet Oncol. 2005;6:659–68.

    Article  PubMed  Google Scholar 

  27. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26:1086–92.

    Article  PubMed  CAS  Google Scholar 

  28. Fiorica F, Di Bona D, Schepis F, et al. Preoperative chemoradiotherapy for esophageal cancer: a systematic review and meta-analysis. Gut. 2004;53:925–30.

    Article  PubMed  CAS  Google Scholar 

  29. Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg. 2003;185:538–43.

    Article  PubMed  Google Scholar 

  30. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–30.

    Article  PubMed  CAS  Google Scholar 

  31. Macdonald JS, Benedetti J, Smalley SR, et al. Chemoradiation of resected gastric cancer: A 10-year follow-up of the phase III trial INT0116 (SWOG 9008). J Clin Oncol. 2009,27S:Abstract 4515.

  32. Heath E, Burtness BA, Heitmiller RF, et al. Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. J Clin Oncol. 2000;18:868–76.

    PubMed  CAS  Google Scholar 

  33. Kleinberg L, Knisely JP, Heitmiller R, et al. Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil and 44 Gy radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2003;56:328–34.

    Article  PubMed  CAS  Google Scholar 

  34. Kleinberg L, Powell ME, Forastiere A, et al. E1201: An ECOG randomized phase II trial of neoadjuvant preoperative paclitaxel/cisplatin/RT or irinotecan/cisplatin/RT in EUS-staged adenocarcinoma of the esophagus. J Clin Oncol 2007;25S:Abstract 4532–4533.

    Google Scholar 

  35. Adelstein DJ, Rice TW, Rybicki LA, et al. Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction. J Thorac Oncol. 2009;4:1264–9.

    Article  PubMed  Google Scholar 

  36. Gaast AV, van Hagen P, Hulshof M, et al. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from a multicenter randomized phase III study. J Clin Oncol 2010;28S:Abstract 4004. This study using modern surgical and radiation techniques provides compelling evidence for the benefit of neoadjuvant chemoradiation.

  37. Adelstein DJ, Rice TW, Rybicki LA, et al. Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. J Clin Oncol. 2000;18:2032–9.

    PubMed  CAS  Google Scholar 

  38. Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27:851–6.

    Article  PubMed  CAS  Google Scholar 

  39. Murthy SC, Rozas MS, Adelstein DJ, et al. Induction chemoradiotherapy increases pleural and pericardical complications after esophagectomy for cancer. J Thorac Oncol. 2009;4:395–403.

    Article  PubMed  Google Scholar 

  40. Abou-Jawde RM, Mekhail T, Adelstein DJ, et al. Impact of induction concurrent chemoradiotherapy on pulmonary function and postoperative acute respiratory complications in esophageal cancer. Chest. 2005;128:250–5.

    Article  PubMed  Google Scholar 

  41. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23:2310–7.

    Article  PubMed  Google Scholar 

  42. Stahl M, Wilke H, Lehmann N, et al. Long-term results of a phase III study investigating chemoradiation with and without surgery in locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2008;26S:Abstract 4530.

  43. Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25:1160–8.

    Article  PubMed  CAS  Google Scholar 

  44. Herskovic A, Martz K, Al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326:1593–8.

    Article  PubMed  CAS  Google Scholar 

  45. Ajani JA, Komaki R, Putnam JB, et al. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer. 2001;92:279–86.

    Article  PubMed  CAS  Google Scholar 

  46. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results. J Thorac Cardiovasc Surg. 2002;124:270–7.

    Article  PubMed  CAS  Google Scholar 

  47. Wang KL, Wu TT, Choi IS, et al. Expression of epidermal growth factor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer. 2007;109:658–67.

    Article  PubMed  CAS  Google Scholar 

  48. Itakura Y, Sasano H, Shiga C, et al. Epidermal growth factor receptor overexpression in esophageal carcinoma: An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer. 1994;74:795–804.

    Article  PubMed  CAS  Google Scholar 

  49. Chan JA, Blaszlowsky LS, Enzinger PC, et al. A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol. 2011;22:1367–73.

    Article  PubMed  CAS  Google Scholar 

  50. Safran H, Suntharalingam M, Dipetrillo T, et al. Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys. 2008;70:391–5.

    Article  PubMed  CAS  Google Scholar 

  51. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer (ToGA): a phase 3, open-label randomized controlled trial. Lancet. 2010;376:687–97.

    Article  PubMed  CAS  Google Scholar 

  52. Kleespies A, Guba M, Jauch KW, et al. Vascular endothelial growth factor in esophageal cancer. J Surg Oncol. 2004;87:95–104.

    Article  PubMed  CAS  Google Scholar 

  53. Karayaninakis AJ, Syrigos KN, Polychronidis A, et al. Circulating VGEF levels in the serum of gastric cancer patients: correlation with pathologic variables, patient survival and tumor surgery. Ann Surg. 2002;236:37–4246.

    Article  Google Scholar 

  54. Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006;24:5201–6.

    Article  PubMed  CAS  Google Scholar 

  55. Kelsen D, Jhawer M, Ilson D, et al. Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF) and bevacizumab in patients with metastatic gastroesophageal adenocarcinoma: Results of a phase II clinical trial. J Clin Oncol 2009;27S:Abstract 4512.

  56. Lordick F, Ott K, Krause B, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the esophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8:797–805.

    Article  PubMed  Google Scholar 

  57. zum Buschenfelde CM, Hermann K, Schuster T, et al. FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. J Nucl Med. 2011;52:1189–96.

    Article  PubMed  Google Scholar 

  58. Yoon HH, Catalano PJ, Murphy KM, et al. Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of ECOG. BMC Cancer. 2011;11:176.

    Article  PubMed  Google Scholar 

  59. Yoon HH, Catalano P, Gibson MK, et al. Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from ECOG. Cancer Chemother Pharmacol. 2011;68:863–70.

    Article  PubMed  CAS  Google Scholar 

  60. Leichman LP, Goldman BH, Bohanes PO, et al. S0356: A phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma. J Clin Oncol. 2011;29:4555–60.

    Article  PubMed  CAS  Google Scholar 

  61. Kelly P, Paulin F, Lamont D, et al. Pre-treatment plasma proteomic markers associated with survival in esophageal cancer. Br J Cancer. 2012;106(5):955–61.

    Google Scholar 

  62. Banki F, Mason RJ, Oh D, et al. Plasma DNA as a molecular marker for completeness of resection and recurrent disease in patients with esophageal cancer. Arch Surg. 2007;142:533–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

M.A. Tejani has nothing to disclose. B. Burtness is a consultant to Boehringer Ingelheim, Novartis, Bristol-Myers Squibb, and Genmab.

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, University of Rochester Wilmot Cancer Center, Rochester, NY, USA

    Mohamedtaki A. Tejani MD

  2. Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA

    Barbara A. Burtness MD

Authors
  1. Mohamedtaki A. Tejani MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barbara A. Burtness MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Barbara A. Burtness MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tejani, M.A., Burtness, B.A. Multi-Modality Therapy for Cancer of the Esophagus and GE Junction. Curr. Treat. Options in Oncol. 13, 390–402 (2012). https://doi.org/10.1007/s11864-012-0193-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-012-0193-5

Keywords

Search

Navigation